Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Clinical Trial of Loncastuximab and Roflumilast Added to R-CHOP (Lo-RR-CHOP) for Treatment Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

NCT06977711 is registered in ClinicalTrials.gov with The University of Texas Health Science Center at San Antonio as lead sponsor.

NCT NCT06977711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06977711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Clinical Trial of Loncastuximab and Roflumilast Added to R-CHOP (Lo-RR-CHOP) for Treatment Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
Lead sponsor
The University of Texas Health Science Center at San Antonio
Phase
Phase 1
Overall status
Recruiting
Start date
June 20, 2025
Completion date
April 1, 2027
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma